Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.04 – $0.36
5% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.8M | $59.5M | $1.1M | $4.0M | $6.1M | $27.1M | $60.3M | $178.0M |
| Cost of revenue | $0 | $0 | $97.5M | $91.6M | $111.1M | $127.7M | $9.9M | $70.0K |
| Gross profit | $37.8M | $59.5M | −$96.4M | −$87.6M | −$104.9M | −$100.6M | $50.4M | $178.0M |
| Gross margin | 100.0% | 100.0% | -8589.9% | -2213.5% | -1706.6% | -370.5% | 83.6% | 100.0% |
| R&D | $87.4M | $98.3M | $97.5M | $91.6M | $111.1M | $127.7M | $126.5M | $149.1M |
| Operating income | −$80.7M | −$82.4M | −$139.8M | −$133.4M | −$162.2M | −$164.0M | −$138.0M | −$68.8M |
| EBITDA | −$75.2M | −$74.6M | −$131.8M | −$125.8M | −$155.7M | −$155.6M | −$128.2M | −$52.7M |
| Net income | −$70.1M | −$95.5M | −$137.2M | −$130.1M | −$158.1M | −$165.5M | −$113.9M | −$70.8M |
| Net margin | -185.4% | -160.5% | -12225.0% | -3286.8% | -2571.0% | -609.5% | -188.9% | -39.8% |
| EPS (diluted) | -0.78 | -0.96 | -1.32 | -0.90 | -1.02 | -1.02 | -0.57 | -0.28 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-0.19 | $-0.36–$-0.01 | 2 |
| 2027 | $116M | $-0.07 | $-0.09–$-0.05 | 1 |
| 2028 | $182M | $-0.08 | $-0.10–$-0.06 | 1 |
| 2029 | $247M | $-0.08 | $-0.10–$-0.06 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ADAP.
No tracked institution reports a position in ADAP as of their last filing.
No one on the platform has traded ADAP yet.
| $2M |
| — |
| GOVXGeoVax Labs, Inc. | $1.32 | +0.76% | $1M | — |
| LNAILunai Bioworks Inc. | $3.21 | -9.83% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 7.6× historical median P/S.
Fair value ≈ $4.73 · price $0.05 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.